Korsana Biosciences, Inc. (KRSA) earnings date
Mar 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Fri, Sep 11, 2026 | after close | 73 | 8-K |
| Q1 FY2023 | Thu, May 11, 2023 | after close | 41 | 8-K |
| Q4 FY2022 | Wed, Mar 22, 2023 | after close | 81 | 8-K |
| Q2 FY2022 | Tue, Aug 9, 2022 | after close | 40 | 8-K |
| Q1 FY2022 | Wed, May 4, 2022 | after close | 34 | 8-K |
| Q4 FY2021 | Thu, Feb 24, 2022 | after close | 55 | 8-K |
| Q3 FY2021 | Tue, Nov 9, 2021 | after close | 40 | 8-K |
What they guided beta
| Q3 FY2026 | "Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., November 5, 2026— Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a" exhibit |
| Q3 FY2026 | "Advanced KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data in patients with Alzheimer’s disease anticipated by year-end 2027 or the first quarter of 2028." exhibit |
| Q3 FY2026 | "o Title: Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation o Session: Poster Session 2, Pre-clinical, Early Discovery and Mechanistic Research o Date: Wednesday, November 18, 2026 Third Quarter 2026 Financial Results Cash Position: Cash and cash equivalents were approximately $456.2 million as of September 30, 2026." exhibit |
| Q3 FY2026 | "The Company expects its cash and cash equivalents to be sufficient to fund operations into 2029." exhibit |
| Q2 FY2026 | "Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer’s patients anticipated by year-end 2027 or first quarter of 2028 Strong financial position with post-transaction cash and cash equivalents of approximately $475 million 1 expected to fund operations into 2029 Shares to begin trading on Nasdaq under ticker symbol “KRSA” on September 9 WALTHAM, Mass., Sept. 0" exhibit |
| Q2 FY2026 | "The combined company will operate under the name Korsana Biosciences, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on September 9, 2026, under the ticker symbol “KRSA.”" exhibit |
| Q2 FY2026 | "This financing, together with existing cash, is expected to support the Company’s operations into 2029, including through multiple clinical milestones for KRSA-028." exhibit |
| Q2 FY2026 | "The Company is advancing KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected in mid-2027 and interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer’s disease patients anticipated by the end of 2027 or the first quarter of 2028." exhibit |
| Q2 FY2026 | "Pro-forma cash as of June 30, 2026, including PIPE, net of projected deal costs." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KRSA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KRSA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/KRSA/"><img src="https://veritasdata.dev/embed/KRSA.svg" alt="KRSA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/KRSA/)
Script
<script async src="https://veritasdata.dev/embed/KRSA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KRSA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.